Transcatheter aortic valve replacement (TAVR) as bridge therapy restoring eligibility for liver transplantation in cirrhotic patients.
Clementine LevyGuillaume LassaillyMehdi El AmraniFlavien VincentCedric DelhayeThibault MeuriceEmmanuel BoleslawskiGuillaume MilletMassih NingarhariStephanie TruantAlexandre LouvetPhilippe MathurinGilles LebuffeFrançois-René PruvotSébastien DharancyPublished in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020)
Severe aortic stenosis is a widespread valve disease, constituting a contraindication to organ transplantation due to cardiovascular morbidity and projected mortality. Mortality after conventional surgical aortic valve replacement in cirrhotic patients depends upon the Child-Pugh class. In the past few years, transcatheter aortic valve replacement has progressively become the treatment of choice for high-risk patients with severe aortic stenosis. Here, we report the cases of 3 cirrhotic patients who became eligible for liver transplantation after successful transcatheter aortic valve replacement as bridge therapy.
Keyphrases
- aortic stenosis
- transcatheter aortic valve replacement
- ejection fraction
- aortic valve replacement
- aortic valve
- transcatheter aortic valve implantation
- left ventricular
- end stage renal disease
- chronic kidney disease
- coronary artery disease
- prognostic factors
- heart failure
- mental health
- early onset
- peritoneal dialysis
- stem cells
- atrial fibrillation
- mesenchymal stem cells
- cell therapy
- combination therapy
- decision making
- bone marrow